Pliant Therapeutics Reports $20M Net Loss in Q1 2026, Down from $56.2M Last Year

Pliant Therapeutics, Inc. reported a net loss of $20.0 million for the first quarter of 2026, a significant decrease from the $56.2 million loss recorded in the same period of the previous year. The company attributed this reduction primarily to a decrease in research and development expenses, which fell to $13.6 million from $43.4 million year-over-year. This decline reflects the discontinuation of the BEACON-IPF Phase 2b trial and a strategic shift in focus towards the development of its lead product candidate, PLN-101095, which is currently in clinical trials for solid tumors.

As of March 31, 2026, Pliant's total assets amounted to $202.6 million, down from $225.2 million at the end of 2025. The decrease in assets was largely driven by a reduction in cash and cash equivalents, which fell to $22.2 million from $45.4 million. The company’s accumulated deficit also increased to $879.4 million, reflecting its ongoing investment in research and development activities. Pliant's total stockholders' equity decreased to $165.2 million from $181.2 million, indicating a continued reliance on external financing to support its operations.

In terms of operational developments, Pliant has initiated the FORTIFY Phase 1b trial, which aims to expand indications for PLN-101095. The trial is currently enrolling patients with non-small cell lung cancer and other solid tumors. The company also presented updated Phase 1 data at the American Association for Cancer Research (AACR) Annual Meeting, highlighting the drug's potential efficacy in combination with pembrolizumab, an existing immunotherapy. These developments are part of Pliant's strategy to leverage its proprietary drug discovery platform, which focuses on integrin-based therapeutics.

Looking ahead, Pliant anticipates continued net losses as it invests in the clinical development of PLN-101095 and other potential product candidates. The company has indicated that it will require substantial additional capital to fund its operations, particularly as it progresses through clinical trials and seeks regulatory approvals. As of the end of the first quarter, Pliant had approximately $172.4 million in cash, cash equivalents, and short-term investments, which it believes will be sufficient to support its operations for the next 12 months. However, the company acknowledges the potential need for further financing to sustain its development efforts and achieve its long-term goals.